Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 81-86 , January 2009

The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer

  • Martin Gleave, M.D.

      Affiliations

    • Department of Urology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
    • ,
  • Laurence Klotz, M.D.

      Affiliations

    • Division of Urology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
    • ,
  • Samir S. Taneja, M.D.

      Affiliations

    • Division of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, NY 10016, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-646-825-6321; fax: +1-646-825-6399

References 

  1. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  2. Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  3. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial (The Medical Research Council Prostate Cancer Working Party Investigators Group). Br J Urol. 1997;79:235–246
  4. Messing EM, Manola J, Yao J, et al. Eastern Cooperative Oncology Group study EST 3886 (Immediate vs. deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy). Lancet Oncol. 2006;7:472–479
  5. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109–4118
  6. Freedland SJ, Humphreys EB, Mangold LA, et al. Changes in body composition during androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603
  7. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–1308
  8. Lee H, McGovern K, Finkelstein JS, et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Cancer. 2005;15:1633–1637
  9. Smith MR, Lee H, Fallon MA, et al. Adipocytes, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318–322
  10. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer. 2008;112:2188–2194
  11. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  12. Dockery F, Bulprit CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia. Aging Male. 2002;5:195–201
  13. Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176:520–525
  14. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–1007
  15. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res. 1977;37:82–94
  16. Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Molec Biol. 1996;58:139–146
  17. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50:2275–2282
  18. Bruchovsky N, Klotz LH, Sadar MD, et al. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol. 2000;4:191–199
  19. Calais-da Silva F, Bono A, Whelan P, et al. Intermittent androgen deprivation for locally advanced prostate cancer (Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group). Oncology. 2003;65(Suppl 1):24–28
  20. Bruchovsky N, Klotz L, Crook J, et al. Locally advanced prostate cancer—biochemical results from a prospective Phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007;109:858–867
  21. Bruchovsky N, Klotz L, Crook J, et al. Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. Cancer. 2006;107:389–395
  22. Foulds L. Neoplastic Development 1. New York: Academic Press; 1969;
  23. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727
  24. Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate. 1984;5:1–17
  25. So AI, Bowden M, Gleave M. Effect of time of castration and tumor volume on time to androgen-independent recurrence in Shionogi tumors. BJU Int. 2004;93:845–850
  26. Iversen P, Johansson JE, Lodding P, et al. Scandinavian Prostatic Cancer Group Bicalutamide (150 mg) vs. placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol. 2004;172:1871–1876
  27. Smith MR. Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007;14:247–254
  28. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev. 2001;1:34–45
  29. Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen. Cancer. 1993;71:2782–2790
  30. Thalmann GN, Anezinis PE, Chang SH, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP Model of human prostate cancer. Cancer Res. 1994;54:2577–2581
  31. Umekita Y, Hiipakka RA, Kokontis JM, et al. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA. 1996;93:11802–11807
  32. Zhou HYE, Chang S-H, Chen B-Q, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA. 1996;93:15152–15157
  33. Russo P, Liguori G, Heston WDW, et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res. 1987;47:5967–5970
  34. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology. 1995;45:839–845
  35. Hurtado-Coll A, Goldenberg SL, Gleave ME, et al. Intermittent androgen suppression in prostate cancer: The Canadian experience. Urology. 2002;60(3 Suppl 1):52–56
  36. Higano CS, Ellis W, Russell K, et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer (A pilot study). Urology. 1996;48:800–804
  37. Grossfeld GD, Small EJ, Lubeck DP, et al. Androgen deprivation therapy for patients with clinically localized (Stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001;58(2 Suppl 1):56–64
  38. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients. BJU Int. 2007;99:1056–1065
  39. Hussain M, Tangen CM, Higano C, et al. Southwest Oncology Group Trial 9346 (INT-0162) (Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)). J Clin Oncol. 2006;24:3984–3990
  40. Albrecht W, Collette L, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study. Eur Urol. 2003;44:505–511
  41. Bruchovsky N, Klotz L, Crook J, et al. Quality of life, morbidity, and mortality results of a prospective Phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer. 2008;6:46–52
  42. Spry NA, Kristjanson L, Hooton B, et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer. 2006;42:1083–1092
  43. Sato N, Akakura K, Isaka S, et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology. 2004;64:341–345

PII: S1078-1439(08)00183-X

doi: 10.1016/j.urolonc.2008.07.025

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 81-86 , January 2009

Article Tools